Literature DB >> 27126598

North American Thrombosis Forum, AF Action Initiative Consensus Document.

Christian T Ruff1, Jack E Ansell2, Richard C Becker3, Emelia J Benjamin4, David J Deicicchi5, N A Mark Estes6, Michael D Ezekowitz7, John Fanikos8, Jawed Fareed9, David Garcia10, Robert P Giugliano11, Samuel Z Goldhaber11, Christopher Granger12, Jeff S Healey13, Russell Hull14, Elaine M Hylek4, Peter Libby11, Renato D Lopes12, Kenneth W Mahaffey15, Jessica Mega11, Gregory Piazza11, Arthur A Sasahara11, Farzaneh A Sorond11, Alex C Spyropoulos2, Jeanine M Walenga9, Jeffrey I Weitz16.   

Abstract

The North American Thrombosis Forum Atrial Fibrillation Action Initiative consensus document is a comprehensive yet practical briefing document focusing on stroke and bleeding risk assessment in patients with atrial fibrillation, as well as recommendations regarding anticoagulation options and management. Despite the breadth of clinical trial data and guideline recommendation updates, many clinicians continue to struggle to synthesize the disparate information available. This problem slows the uptake and utilization of updated risk prediction tools and adoption of new oral anticoagulants. This document serves as a practical and educational reference for the entire medical community involved in the care of patients with atrial fibrillation.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Anticoagulants; Antithrombotic management; Atrial fibrillation; Bleeding risk; Stroke

Mesh:

Substances:

Year:  2016        PMID: 27126598     DOI: 10.1016/j.amjmed.2016.02.001

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  4 in total

1.  Performance of the microINR Point-of-Care System Used by Self-Testing Patients: A Multicenter Clinical Trial.

Authors:  Majed A Refaai; Alan K Jacobson; Jack C Rosenfeld; Robert R Orr
Journal:  TH Open       Date:  2021-12-30

2.  Recombinant activated factor VII (rFVIIa) in refractory haemorrhage for non-haemophiliacs: an eleven-year single-centre experience.

Authors:  Nurfatin Mohd Shah; Soon Eu Chong; Syahirah Mohamed Yusoff; Mohd Zulfakar Mazlan; Khairul Bariah Johan; Nizuwan Azman; Jo Anne Lim; Siti Mardhiana Mohamad; Siti Salmah Noordin; Zainab Abdul Ghaffar; Mohd Hasyizan Hassan; Muhammad Azrul Zabidi; Nur Arzuar Abdul Rahim
Journal:  BMC Hematol       Date:  2018-11-23

3.  Phenome-wide association studies across large population cohorts support drug target validation.

Authors:  Dorothée Diogo; Chao Tian; Christopher S Franklin; Mervi Alanne-Kinnunen; Michael March; Chris C A Spencer; Ciara Vangjeli; Michael E Weale; Hannele Mattsson; Elina Kilpeläinen; Patrick M A Sleiman; Dermot F Reilly; Joshua McElwee; Joseph C Maranville; Arnaub K Chatterjee; Aman Bhandari; Khanh-Dung H Nguyen; Karol Estrada; Mary-Pat Reeve; Janna Hutz; Nan Bing; Sally John; Daniel G MacArthur; Veikko Salomaa; Samuli Ripatti; Hakon Hakonarson; Mark J Daly; Aarno Palotie; David A Hinds; Peter Donnelly; Caroline S Fox; Aaron G Day-Williams; Robert M Plenge; Heiko Runz
Journal:  Nat Commun       Date:  2018-10-16       Impact factor: 14.919

Review 4.  Practical perspectives on the use of non-vitamin K antagonist oral anticoagulants for stroke prevention in patients with nonvalvular atrial fibrillation: A view from the Middle East and North Africa.

Authors:  Ahmad S Hersi; Yahya S Alhebaishi; Omar Hamoui; Taher Hassan; Adel Khalifa Hamad; Mohamed Magdy; Hani Sabbour; Sameh Shaheen
Journal:  J Saudi Heart Assoc       Date:  2017-06-08
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.